AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03181815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5mg/㎡ d1-5
Study NCT03181815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300ug d0-9
Study NCT03181815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclarubicin
Description: 10mg d3-6
Study NCT03181815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10mg/㎡ q12h SC d3-9
Study NCT01948037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hydrotherapy
Description: 30-minutes/per day,for 4weeks
Study NCT04405908 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019 with AS03 adjuvant
Description: SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
Study NCT04405908 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant
Description: SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
Study NCT04405908 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019 with Alum adjuvant
Description: SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
Study NCT00348153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT00348153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT03915561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib Injectable Product
Description: Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
Study NCT03915561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
Study NCT03969641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
Study NCT03969641 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
Study NCT03455036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: 10 x 1 min whole body vibration exposure
Study NCT03293771 — intervention group
Intervention type: OTHER
Intervention: Focus group interviews
Description: Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
Study NCT03293771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire packet
Description: Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
Study NCT03180255 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: Ocular iontophoretic delivery of a steroid
Study NCT03180255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocular iontophoretic delivery of a placebo
Study NCT02105909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GWAS
Study NCT02105909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GWAS
Study NCT01948037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: 30-minutes/per day,for 4weeks
Study NCT01948037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hydrotherapy
Description: 30-minutes/per day;4weeks
Study NCT01948037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: 30-minutes/per day;4weeks
Study NCT02575742 — intervention group
Intervention type: DEVICE
Intervention: 3D-Transit system
Study NCT02664610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: hypertensive participants will be randomized to receive tailored, motivational text messages
Study NCT02605785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV 1451
Description: Tau PET scan
Study NCT04224389 — intervention group
Intervention type: PROCEDURE
Intervention: transoral resection
Description: The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.
Study NCT04224389 — intervention group
Intervention type: RADIATION
Intervention: IMRT
Description: Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
Study NCT01352364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy intervention
Description: a program of physical therapy intervention can match or improve motor skills in the deaf children
Study NCT02176278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Reminder
Description: Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
Study NCT02176278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doctor-Nurse Follow Up
Description: Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
Study NCT02176278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Risk Report for Patient Empowerment
Description: Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
Study NCT02412722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules
Study NCT02412722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel injection
Study NCT04666597 — intervention group
Intervention type: PROCEDURE
Intervention: Modified CariesCare International management
Description: Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment.
Study NCT04337229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artifical intelligent
Description: it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
Study NCT02773433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation
Study NCT01130103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
Study NCT01556867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord care by simple debridement (soaping, rinsing and drying)
Description: For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
Study NCT01556867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord care with the use of antiseptics
Description: For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care.
Study NCT00876720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS - Intervention 1
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
Study NCT00876720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS - Intervention 2
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
Study NCT03957694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
Study NCT02129517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Description: Tailored, web-based educational short video clips
Study NCT02129517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online education materials
Description: Online NCI-based educational materials
Study NCT02129517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT02129517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies
Study NCT01130103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Weekly for 10 weeks
Study NCT01321905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with vitamin D2/D3
Description: Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.
Study NCT04951843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black soybean koji product
Description: Black soybean koji product
Study NCT03116178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group G -PVI( Masimo co oximeter) guided fluid therapy
Description: goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered
Study NCT03116178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B- Body weight guided intravenous fluid @6-8ml/kg
Description: Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
Study NCT00873886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir (Tamiflu)
Description: The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected.
Study NCT00873886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draws
Description: Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
Study NCT02407938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice meal
Study NCT01588925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Description: Cochlear implantation using Hybrid L24 Implant
Study NCT01588925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation
Description: Cochlear implantation using Hybrid L24 Implant
Study NCT01588925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation+dexamethasone
Description: Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
Study NCT01588925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implantation+dexamethasone+hyaluronic acid
Description: Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
Study NCT01566565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline and Bambuterol
Description: Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
Study NCT01130103 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Weekly for 10 weeks
Study NCT02839928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
Study NCT02839928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal atomizer
Description: Ketamine will be applied to each nare via intranasal atomizer
Study NCT02839928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Study NCT02361697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DTI-MRI
Description: MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
Study NCT02399995 — intervention group
Intervention type: BEHAVIORAL
Intervention: HRQoL questionnaires.
Description: Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.
Study NCT01422382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin (NK-104)
Description: pitavastatin (NK-104) 4 mg once daily (QD)
Study NCT01422382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem (Cardizem LA) 240 mg QD
Description: Diltiazem (Cardizem LA) 240 mg QD
Study NCT01514422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 to 300mg per day for 8 weeks
Study NCT04319731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Fluid
Description: Administration of amniotic fluid in SARS-CoV-2 positive patients
Study NCT02857985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D RA
Description: 3D RA is realised just after angioplasty.
Study NCT00245154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00245154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00245154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00245154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00245154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00245154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02106546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
Study NCT02106546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
Study NCT02106546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules taken orally twice a day, 12 hours apart.
Study NCT02106546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
Study NCT02106546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
Study NCT02106546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to veliparib
Description: Capsules taken orally twice a day, 12 hours apart.
Study NCT01271231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing plus placebo
Description: Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
Study NCT01271231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus azythromycin
Description: Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Study NCT01271231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylaxis plus azythromycin
Description: Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
Study NCT01373411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: ticagrelor 90 mg BID for 90 days
Study NCT01373411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill BID for 90 days
Study NCT02002715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide
Description: inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Study NCT02857985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI is realised between 24h and 96h post angioplasty.
Study NCT03074669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT program
Description: ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
Study NCT03868280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade femoral nailing Supine Position
Description: Antegrade femoral nailing in Supine Position using a Fracture Table
Study NCT03868280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade Femoral Nailing Lateral Position
Description: Antegrade femoral nailing in Lateral Position using a Free drape